A director at Canadian Gold Corp sold 185,560 shares at 0.235CAD and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream NEW YORK, Jan. 11, 2024 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs.” To hear the AudioPressRelease, please visit: To view the full editorial, please visit: With each new study, the horizon of GLP-1’s therapeutic potential expands, painting a vibrant picture of a future where a single molecule could tackle a multitude of ...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform NEW YORK, Jan. 09, 2024 (GLOBE NEWSWIRE) -- via — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by ("NNW"), one of 60+ brands within the @ (), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the full publication, “Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs,” please visi...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Studies of Proprietary Platform in Multibillion-Dollar GLP-1 Drug Space NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Can Diabetes, Weight-Loss Drugs Get Even Better?” To hear the AudioPressRelease, please visit: To view the full editorial, please visit: It shouldn’t be surprising that analysts at Markets and Research estimate the global diabetes drug market at $63.1 billion in 2021 on its way to $82.93 billion in 2027, while th...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 Drugs NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- via — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by ("NNW"), one of 60+ brands within the @ (), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the full publication, “Can Diabetes, Weight-Loss Drugs Get Even Better?”,please visit: The prest...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Focused on Filling Need for Hypertension Treatment Solution NEW YORK, Aug. 11, 2022 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “The Power of Science to Stop a Killer.” To hear the AudioPressRelease, please visit: To view the full editorial, please visit: In its 2021 industry report, estimated the global anti-hypertensive drugs market at $24.17 billion in 2020 on its way to reach $27.81 billion in 2025. All told, hypertension costs the country on average ann...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Developing Powerful Tech to Treat Hypertension NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) -- via — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by ("NNW"), one of 50+ trusted brands within the (“IBN”), a multifaceted financial news and publishing company for private and public entities. To view the full publication, “The Power of Science to Stop a Killer,” please visit: Nearly half of all American adults suffer from hypertension (high blood pressure), often referred to as a silent killer. More ...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Stands as Global Leader in Delivery Tech Space NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Nicotine Surges as Smoking Sags.” To hear the AudioPressRelease, please visit: To view the full editorial, please visit: The fact remains that an estimated 1.1 billion people smoked cigarettes in 2019. According to stats from the World Health Organization, a stunning 780 million people said they want to quit. As a result, people look to a multitud...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Offers Breakthrough Delivery Tech in Hot Nicotine Space NEW YORK, May 25, 2022 (GLOBE NEWSWIRE) -- via — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by ("NNW"), one of 50+ trusted brands within the (“IBN”), a multifaceted financial news and publishing company for private and public entities. To view the full publication, “Nicotine Surges as Smoking Sags,” please visit: Seems like yesterday people were smoking cigarettes everywhere; many people still have memories of Grandpa puffing on his Ca...
CANOPY GROWTH (CA), a company active in the Pharmaceuticals industry, slightly increases its general evaluation. The independent financial analyst theScreener just confirmed the stock market behaviour of the title as risky. At the fundamental level, theScreener confirms the rating of 0 out of 4 stars; given the more favourable environment, the title's overall rating is upgraded to Slightly Negative even if it remains under pressure. As of the analysis date March 18, 2022, the closing price was C...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Emerging as Leader in Pursuit of More-Effective Hypertension Treatment NEW YORK, Sept. 16, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Hypertension: The Silent Killer Making Loud Noise for Investors.” To hear the AudioPressRelease, please visit: To view the full editorial, please visit: The market is certainly worth entering. Consider that Reportlinker.com estimates the global anti-hypertensive drugs market to be $24.37 billion in 2021 and growing 3.4% an...
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Throw Hat into Hypertension Ring with Proprietary Drug-Delivery System NEW YORK, Sept. 15, 2021 (GLOBE NEWSWIRE) -- via — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by ("NNW"), one of 50+ trusted brands within the (“IBN”), a multifaceted financial news and publishing company for private and public entities. To view the full publication, “Hypertension: The Silent Killer Making Loud Noise for Investors,” please visit: Hypertension, or high blood pressure, is rampant in America. An estimat...
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
Lexaria Bioscience Corp. (NASDAQ: LEXX) on Forefront of Exciting Hypertension Innovation NEW YORK, Aug. 06, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Cardiovascular Disease Drug Market Offers Compelling Potential for First Movers, Innovators in the Space.” To hear the AudioPressRelease, please visit: To view the full editorial, please visit: Controlling blood pressure is essential to health. High blood pressure is a primary or contributing cause of death in almost 500,000 deaths a year, and...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Leads the Way in Innovating Hypertension Treatment NEW YORK, Aug. 04, 2021 (GLOBE NEWSWIRE) -- via — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by ("NNW"), one of 50+ trusted brands within the (“IBN”), a multifaceted financial news and publishing company for private and public entities. To view the full publication, “Cardiovascular Disease Drug Market Offers Compelling Potential for First Movers, Innovators in the Space,” please visit: One of the most pervasive diseases in first-world count...
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.